Ukulandelana kwesikhathi eside kwe-COVID-19

UJennifer Mihas wayevame ukuphila impilo esebenzayo, edlala ithenisi futhi ehambahamba eSeattle. Kepha ngoMashi 2020, wahlolelwa ukuthi une-COVID-19 futhi wagula kusukela lapho. Ngalesi sikhathi wayesekhathele ukuhamba amakhulukhulu amagceke, futhi wayehlushwa ukuphefumula, ama-migraines, i-arrhythmias nezinye izimpawu ezikhubazayo.

Lawa akuwona amacala ahlukile. Ngokwe-US Centers for Disease Control and Prevention, amaphesenti ayi-10 kuya kwangama-30 abantu abangenwe yiSARS-CoV-2 babhekana nezinkinga zesikhathi eside zezempilo. Eziningi zazo zifana neMihas, lezi zimpawu eziphikelelayo, ezaziwa njenge-acute sequelae yokutheleleka kwe-SARS-CoV-2 (PASC) noma, ngokujwayelekile, i-sequelae yesikhathi eside ye-COVID-19, ingaba mnene noma ibe nzima ngokwanele ukuthi ingakhubaza, kuthinta cishe noma yiluphi uhlelo lwesitho emzimbeni.

news-2

Abantu abathintekile bavame ukubika ukukhathala okukhulu nobuhlungu bomzimba. Abantu abaningi balahlekelwa umuzwa wokunambitha noma wokuhogela, ubuchopho babo buyehla futhi abakwazi ukugxila, okuyinkinga ejwayelekile. Ochwepheshe bakhathazekile ngokuthi ezinye iziguli ezine-sequelae yesikhathi eside ye-COVID-19 kungenzeka zingalulami.

Manje, ukulandelana kwesikhathi eside kwe-COVID-19 kuya ngokuya kugqame. NgoFebhuwari, i-NATIONAL Institutes of Health yamemezela isinyathelo esingu- $ 1.15 billion sokuthola izimbangela zesikhathi eside se-COVID-19 nokuthola izindlela zokunqanda nokwelapha lesi sifo.

Ukuphela kukaJuni, abantu abangaphezu kwezigidi eziyi-180 bebehlolwe benegciwane le-SARS-CoV-2, kanti amakhulu ezigidi ezinye kungenzeka ukuthi atheleleke nge-SARS-CoV-2, kuthuthukiswa nemithi emisha ukubhekana nenani elikhulu izinkomba ezintsha ezingaba khona kwezokwelapha.

IPureTech Health iqhuba isigaba sesibili sokuhlolwa kohlobo lwe-pirfenidone, i-LYT-100. IPirfenidone ivunyelwe i-idiopathic pulmonary fibrosis. I-Lyt-100 ihlose ama-cytokines angama-pro-inflammatory, kufaka phakathi i-IL-6 ne-TNF-α, futhi inciphisa ukusayinda kwe-TGF-to ukuvimba ukubekwa kwe-collagen nokwakheka kwesibazi.

ICytoDyn ihlola i-CC motactic chemokine receptor 5 (CCR5) ye-antagonist leronlimab, i-anti-IgG4 monoclonal antibody yayo, esigabeni sesibili sokuhlolwa kwabantu abangama-50. I-CCR5 ibandakanyeka ezinkambisweni eziningi zezifo, kufaka phakathi i-HIV, i-multiple sclerosis, nomdlavuza we-metastatic. ILeronlimab ihlolwe esigabeni 2B / 3 kokuhlolwa kwemitholampilo njengokwelashwa okungeziwe kwezifo zokuphefumula ezigulini ezibucayi ezine-COVID-19. Imiphumela ikhombisa ukuthi umuthi unenzuzo yokuphila uma kuqhathaniswa nezindlela zokwelapha ezisetshenziswa kakhulu, kanti isifundo samanje sesigaba 2 sizophenya umuthi njengokwelashwa kwezimpawu ezahlukahlukene.

I-Ampio Pharmaceuticals ibike imiphumela emihle yesigaba 1 ye-cyclopeptide LMWF5A (aspartic alanyl diketopiperazine), elapha ukuvuvukala ngokweqile emaphashini, kanti i-Ampio ithi i-peptide inyuse konke okubangela ukufa kweziguli ezinenkinga yokuphefumula. Esivivinyweni esisha sesiGaba 1, iziguli ezinezimpawu zokuphefumula ezihlala amasonto amane noma ngaphezulu zizozenzela ekhaya ne-nebulizer izinsuku ezinhlanu.

ISynairgen e-United Kingdom isebenzise indlela efanayo ukwengeza i-COVID-19 sequelae yesikhathi eside esivivinyweni somtholampilo sesigaba 3 se-SNG001 (ihogelwe i-IFN-β). Imiphumela evela ocwaningweni lwesigaba 2 somuthi ikhombise ukuthi i-SNG001 ibilusizo ekuthuthukiseni isiguli, ukululama, nokukhipha uma kuqhathaniswa ne-placebo ngosuku lwe-28.


Isikhathi Iposi: 26-08-21